Baker Tilly

Loading...

Subscribe to newsletters
About Us
Careers
Client Portals
Pay Invoice
Locations
Industries
Services
Professionals
Legal & Privacy
CCPA Privacy
Contact Us
Request a Proposal

© 2024-2026 Baker Tilly US, LLP / Baker Tilly Advisory Group, LP

Baker Tilly US, LLP and Baker Tilly Advisory Group, LP and its subsidiary entities provide professional services through an alternative practice structure in accordance with the AICPA Code of Professional Conduct and applicable laws, regulations and professional standards. Baker Tilly US, LLP is a licensed independent CPA firm that provides attest services to clients. Baker Tilly Advisory Group, LP and its subsidiary entities provide tax and business advisory services to their clients. Baker Tilly Advisory Group, LP and its subsidiary entities are not licensed CPA firms.

Baker Tilly Advisory Group, LP and Baker Tilly US, LLP are independent members of Baker Tilly International. Baker Tilly International Limited is an English company. Baker Tilly International provides no professional services to clients. Each member firm is a separate and independent legal entity and each describes itself as such. Baker Tilly Advisory Group, LP and Baker Tilly US, LLP are not Baker Tilly International’s agent and do not have the authority to bind Baker Tilly International or act on Baker Tilly International’s behalf. None of Baker Tilly International, Baker Tilly Advisory Group, LP, Baker Tilly US, LLP, nor any of the other member firms of Baker Tilly International has any liability for each other’s acts or omissions. The name Baker Tilly and its associated logo is used under license from Baker Tilly International Limited.

team member talking digital screen

Article

The copay governance model

A CFO’s framework for oversight in an increasingly complex affordability environment

April 22, 2026

Subscribe to newsletters

Share

Related sections

  • Government Contractors
  • Healthcare
  • Life Science Gross-To-Net Assistance & Outsourcing Services
  • Life Sciences
  • Risk Advisory

Executive summary

Copay assistance programs have evolved from tactical affordability tools into one of the most significant financial and operational levers within pharmaceutical commercialization.

Today, these programs sit at the intersection of:

  • Patient access
  • Payer design
  • Pharmacy adjudication
  • Gross-to-net (GTN) economics
  • Financial reporting and compliance

As a result, copay programs are no longer peripheral. They are central to how value flows through the healthcare system. Yet in many organizations, governance models have not kept pace with this evolution.

This article introduces a structured copay governance model designed for CFOs and financial leadership teams. It reframes copay programs as a system requiring active oversight, not a static affordability benefit.

The core premise is simple:

Copay programs do not just support access.

They shape financial outcomes.

The evolution of copay: From support tool to system driver

Copay assistance programs were originally designed to reduce out-of-pocket costs and improve therapy initiation and adherence. Over time, however, several structural changes have transformed the role of these programs:

  • Increased reliance on high-cost specialty therapies
  • Growth of payer cost-sharing and deductible structures
  • Expansion of the pharmacy benefit manager (PBM) influence
  • Emergence of accumulator and maximizer programs

These changes have created a new reality, and copay programs now operate inside a complex, multi-party system that directly influences pricing realization and revenue integrity. Recent industry developments highlight this shift:

Related sections

  • Government Contractors
  • Healthcare
  • Life Science Gross-To-Net Assistance & Outsourcing Services
  • Life Sciences
  • Risk Advisory
  1. PBM-driven copay accumulator and maximizer programs have expanded significantly, altering how manufacturer-funded assistance is applied at the point of sale.
  2. Increased scrutiny from policymakers and advocacy groups has raised concerns about whether manufacturer affordability investments are reaching patients as intended.
  3. Growth in real-time benefit tools and eVoucher systems has introduced new pathways for how copay support is triggered and applied, often outside manufacturer visibility.

In this environment, copay is no longer a simple transaction but a dynamic system interaction.

Copay within the GTN ecosystem

To understand why governance matters, copay programs must be viewed within the broader GTN ecosystem. Copay does not operate in isolation; it interacts with multiple components of the commercialization and financial process, including:

  • Patient demand, where affordability influences therapy initiation and adherence
  • Channel dynamics, where payer design and pharmacy pathways determine how access is executed
  • Operational activity, where copay claims are recorded alongside rebates, chargebacks and other program transactions
  • Financial estimation, where liabilities are modeled through accruals and reserve methodologies
  • Financial reporting, where outcomes are reflected in revenue recognition, variance analysis and external disclosures

While copay activity is most visible at the point of transaction, it is shaped by upstream decisions and has downstream implications that extend into financial performance and reporting. When these elements are not aligned, organizations may experience:

  • Distorted demand signals
  • Unanticipated liability growth
  • Variability in forecasting accuracy
  • Increased financial reporting and compliance risk

In this context, copay programs should not be viewed solely as affordability tools or cost centers. Instead, they function as system-level control points, influencing both patient access outcomes and the integrity of GTN financial results.

Why copay governance has become a CFO issue

Historically, copay programs were managed within patient access or marketing functions. Today, their financial impact requires direct CFO oversight.

Key reasons include:

Manufacturer-funded copay programs now represent billions of dollars annually across the industry.

Every copay claim contributes to net price realization, accrual methodologies and margin performance.

Programs now interact with PBM logic, pharmacy workflows and digital adjudication pathways.

Copay programs are increasingly scrutinized for:

  • Compliance with federal and state regulations
  • Alignment with intended patient benefit
  • Transparency in financial reporting

What was once operational is now financial. What was once tactical is now strategic.

The copay governance model

An effective governance framework includes four core components: 

1. Program design oversight

2. Vendor and adjudication governance

3. Distribution network monitoring

4. Financial integration and reporting alignment

Copay programs must balance affordability with financial and compliance discipline. 

Key elements: 

  • Clear eligibility criteria tied to clinical use 
  • Defined benefit caps and utilization controls 
  • Alignment with payer coverage dynamics 
  • Guardrails to prevent unintended utilization patterns 

Example: 

Several manufacturers have adjusted copay program structures in response to maximizer programs, introducing monthly caps or eligibility verification steps to prevent unlimited benefit capture by third parties.

Most programs rely on third-party administrators and adjudication platforms. Without proper oversight, visibility is limited. 

Governance requires: 

  • Claims-level data transparency 
  • Understanding of adjudication pathways (e.g., primary vs secondary payer sequencing) 
  • Monitoring of eVoucher activation logic 
  • Independent audit capabilities

Example:

The rise of real-time eVoucher systems, often integrated through switch vendors, has created scenarios where copay is applied automatically at the point of sale, sometimes without full manufacturer visibility into payer sequencing or downstream impact.

Retail pharmacies, specialty pharmacies, PBMs, hubs and eHubs. Each participant influences how benefits are applied. 

Monitoring should include: 

  • Pharmacy-level utilization patterns 
  • Reversal and reprocessing activity 
  • Substitution behavior 
  • Alignment between expected and observed usage 

Example: 

Industry analyses and audits have identified cases where claims are reversed and reprocessed to maximize copay benefit application, highlighting the need for active monitoring of pharmacy-level behavior.

Copay programs must be integrated into financial governance structures. This includes: 

  • Alignment with GTN accrual methodologies 
  • Validation of forecasting assumptions 
  • Coordination between finance, compliance and access teams 

Example: 

Organizations have experienced significant variance between forecasted and actual copay spend due to changes in payer behavior (e.g., maximizers, accumulators), requiring retrospective adjustments to accruals and financial disclosures.

Where copay governance breaks today

Despite increased investment, several systemic issues persist:

Manufacturers often lack real-time insight into:

  • How benefits are applied
  • Who ultimately receives value
  • How payer logic influences outcomes

Different stakeholders optimize for different outcomes:

  • PBMs for cost management
  • Pharmacies for transaction volume
  • Manufacturers for access and adherence

This creates friction and inefficiency.

Copay assistance may:

  • Be redirected through maximizer programs
  • Be applied inconsistently across channels
  • Fail to reach intended patients

Data is distributed across vendors, pharmacies, payers and internal systems. This fragmentation limits effective governance.

The absence of strong governance creates material risks, which can include:

  • Accrual inaccuracies due to incomplete utilization data
  • Revenue leakage from unintended benefit application
  • Audit exposure related to program design and execution
  • Regulatory scrutiny tied to affordability program practices

As scrutiny increases, organizations must ensure that operational execution aligns with financial reporting.

The future of copay governance

The next phase of copay evolution will be defined by:

Demand for visibility across the full patient journey will continue to grow.

Manufacturers may seek greater control over how copay is applied, separate from existing pharmacy or PBM-controlled pathways.

Linking:  

  • Patient activity 
  • Channel behavior 
  • Financial outcomes 

In near-real time

Connecting affordability programs to broader GTN strategy, not treating them as standalone tools.

Conclusion

Copay programs have evolved beyond being just simple affordability mechanisms. They now serve as:

  • Financial instruments
  • Access enablers
  • System control points

They require governance accordingly.

For CFOs and financial leaders, the goal is clear: transition from managing copay as a program to governing it as a system. In today’s environment, access, economics and financial outcomes are no longer separate; they are interconnected and must be managed that way.

Through a governance‑driven approach, Baker Tilly helps organizations strengthen oversight of copay programs and better align access strategies with predictable, defensible GTN financial results. Connect with a Baker Tilly specialist today to discuss more.

Connect with us